newsfilter
← Latest News
GlobeNewswire·

I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025

ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer,